Registration statement

Inpixon Announces Record Date and Details for Subsidiary Spin-off and its Planned Business Combination with Damon Motors

Retrieved on: 
Thursday, December 14, 2023
Aircraft, PALO, Spin, Business analyst, Security (finance), Registration statement, Date, IIOT, Supreme court, Internet of things, Arrangement, Motorcycle, Hand, Register, Business, Life insurance, Distrito Grafiti (TransMilenio)

PALO ALTO, Calif., Dec. 14, 2023 /PRNewswire/ -- Inpixon® (Nasdaq: INPX) today announced that its board of directors has set December 27th, 2023 as the record date ("Record Date") for determining the holders of Inpixon's outstanding capital stock and certain other securities (the "Record Date Securityholders") entitled to the distribution of all the outstanding shares of Grafiti Holding Inc. ("Grafiti") owned by Inpixon (the "Spin-off Shares") in connection with its previously announced spinoff ("Spin-off").  

Key Points: 
  • The Spin-off is required to be completed prior to the planned business combination between Grafiti and Damon Motors, Inc. ("Damon"), the maker of the acclaimed HyperSport electric motorcycle ("Business Combination").
  • Nadir Ali, CEO of Inpixon said, "I'm pleased to report we are making progress with the planned Spin-off and the anticipated business combination of Grafiti with Damon.
  • Inpixon expects that there will be no public trading market for the shares of Grafiti until or unless the Business Combination is consummated.
  • Inpixon may elect to change the Record Date for the Spin-off to a later date or to not proceed with the distribution.

DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Acelyrin, Inc. (NASDAQ: SLRN) and Lead Plaintiff Deadline

Retrieved on: 
Tuesday, December 12, 2023
Abscess, NYSE, SAN, Registration statement, Initial public offering, Form, Patient, Hidradenitis suppurativa, HS, SLRN, IPO, Register, News, Pharmaceutical industry, Part

The lawsuit charges Acelyrin and certain of its senior executive officers with violations of the Securities Exchange Act of 1934.

Key Points: 
  • The lawsuit charges Acelyrin and certain of its senior executive officers with violations of the Securities Exchange Act of 1934.
  • You can also contact DiCello Levitt partner Brian O'Mara by calling (888) 287-9005 or at [email protected] .
  • An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
  • The Acelyrin lawsuit alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

Vaso Corporation, a Diversified Medical Technology Company Currently Trading on the OTCQX Market, to List on Nasdaq via SPAC Merger

Retrieved on: 
Thursday, December 7, 2023
Sale, Transaction, Radiological information system, Combination, Registration statement, LLP, System, OTCQX, Form, Ladenburg Thalmann, File, Software, Security (finance), Achari, Vaso

The transaction values Vaso at a pro forma equity value of approximately $176 million at $10 per share.

Key Points: 
  • The transaction values Vaso at a pro forma equity value of approximately $176 million at $10 per share.
  • Upon closing of the transaction, existing Vaso shareholders will receive consideration consisting entirely of shares of the surviving public combined company.
  • PLAINVIEW, NY, Dec. 7, 2023 /PRNewswire/ - Vaso Corporation ("Vaso," or "the Company"), a diversified medical technology company currently trading on the OTCQX market, today announced its plan to uplist from the OTCQX market to the Nasdaq Stock Market via a business combination (the "Transaction") with Achari Ventures Holdings Corp.
  • Katten Muchin Rosenman LLP is acting as legal advisor to Achari and Ortoli Rosenstadt LLP is acting as legal advisor to Vaso.

Realty Income Prices £750 Million Dual-Tranche Offering of Sterling-Denominated Senior Unsecured Notes

Retrieved on: 
Tuesday, November 28, 2023
Sale, Suite, Acquisition, Wells Fargo, NYSE, Telephone, SAN, Registration statement, Bishopsgate, BNP Paribas, Prospectus, BofA Securities, RBC Capital Markets, ATTN:, Register, Security (finance), Realty Income, Barclays

SAN DIEGO, Nov. 28, 2023 /PRNewswire/ -- Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced the pricing of a public offering of £300 million of 5.750% senior unsecured notes due December 5, 2031 (the "2031 notes"), and £450 million of 6.000% senior unsecured notes due December 5, 2039 (the "2039 notes").

Key Points: 
  • SAN DIEGO, Nov. 28, 2023 /PRNewswire/ -- Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced the pricing of a public offering of £300 million of 5.750% senior unsecured notes due December 5, 2031 (the "2031 notes"), and £450 million of 6.000% senior unsecured notes due December 5, 2039 (the "2039 notes").
  • Combined, the notes have a weighted average tenor of approximately 12.8 years, a weighted average annual yield to maturity of 5.990%, and a weighted average coupon rate of 5.900%.
  • This offering is expected to close on December 5, 2023, subject to the satisfaction of customary closing conditions.
  • The active joint book-running managers for the offering are Wells Fargo Securities, Barclays, BNP Paribas, BofA Securities and RBC Capital Markets.

CorpAcq and Churchill Capital Corp VII Announce Filing of Registration Statement on Form F-4 in Connection with Proposed Business Combination and CorpAcq's First Half 2023 Results

Retrieved on: 
Friday, November 17, 2023
EBITDA, Acquisition, NYSE, LLP, Registration statement, Weil, Gotshal & Manges, Transaction, Form, CVII, Tripura Merger Agreement, Register, UBS, Growth, Security (finance), Bookkeeping

The Registration Statement contains a proxy statement/prospectus in connection with the definitive agreement entered into between Churchill VII, CorpAcq and CorpAcq Group with respect to the proposed business combination (the "Merger Agreement", and the transactions contemplated thereby, the "Transactions").

Key Points: 
  • The Registration Statement contains a proxy statement/prospectus in connection with the definitive agreement entered into between Churchill VII, CorpAcq and CorpAcq Group with respect to the proposed business combination (the "Merger Agreement", and the transactions contemplated thereby, the "Transactions").
  • While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about CorpAcq, CorpAcq Group, Churchill VII and the Transactions.
  • As announced on August 1, 2023, CorpAcq intends to go public through a business combination with Churchill VII.
  • Further information on CorpAcq's financial performance for the first six months of 2023 is available in the Registration Statement.

RumbleOn Announces Subscription Price for its $100.0 Million Rights Offering

Retrieved on: 
Thursday, November 9, 2023
Recreational Vehicles, Software, Performance & Special Interest, Sports, Online Retail, Motor Sports, Specialty, Technology, Aftermarket, Automotive, Extreme Sports, Retail, Other Automotive, Registration statement, Sale, Register, Rights, Date, Exercise, Prospectus, FC Volna Pinsk, Subscription business model, Class, Shareholder, Security (finance)

RumbleOn, Inc. (NASDAQ: RMBL) (the “Company” or “RumbleOn”) announced today that it has set a subscription price of $5.50 per share (the “Subscription Price”) of the Company’s Class B common stock to be paid upon exercise of the Subscription Rights (as defined below) to be distributed to the holders of its Class A common stock and Class B common stock (together, the “Eligible Stockholders”) pursuant to its previously announced $100.0 million rights offering (the “Rights Offering”).

Key Points: 
  • RumbleOn, Inc. (NASDAQ: RMBL) (the “Company” or “RumbleOn”) announced today that it has set a subscription price of $5.50 per share (the “Subscription Price”) of the Company’s Class B common stock to be paid upon exercise of the Subscription Rights (as defined below) to be distributed to the holders of its Class A common stock and Class B common stock (together, the “Eligible Stockholders”) pursuant to its previously announced $100.0 million rights offering (the “Rights Offering”).
  • Under the terms of the Rights Offering, the Company expects to distribute non-transferable subscription rights to purchase shares of Class B common stock (the “Subscription Rights”) to the Eligible Stockholders as of November 13, 2023 (the “Record Date”).
  • Each Subscription Right will entitle such Eligible Stockholder to purchase 1.078444 shares of the Company’s Class B common stock at the Subscription Price.
  • The subscription period for the Rights Offering is expected to commence on or about November 13, 2023 and end on November 28, 2023, unless extended.

Tiptree Announces Fortegra Filing of Registration Statement for Initial Public Offering

Retrieved on: 
Wednesday, November 8, 2023
Professional Services, Insurance, Finance, IPO, Register, Sale, Security (finance), Barclays, J. P. Morgan, Jefferies Group, TIPT, Telephone, Registration statement, Form, Attention, Prospectus, Jefferies, Broadridge Financial Solutions, Inc.

Tiptree Inc. (“Tiptree”) (NASDAQ:TIPT) today announced that its specialty insurance subsidiary, The Fortegra Group, Inc. (“Fortegra”) has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”).

Key Points: 
  • Tiptree Inc. (“Tiptree”) (NASDAQ:TIPT) today announced that its specialty insurance subsidiary, The Fortegra Group, Inc. (“Fortegra”) has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”).
  • The size of the proposed offering and price range for the proposed offering have not yet been determined.
  • Tiptree expects to maintain majority ownership of Fortegra and believes a Fortegra IPO will create a platform to serve the future capital needs of the business.
  • The Registration Statement related to these securities has been filed with the SEC but has not yet become effective.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – KVUE

Retrieved on: 
Tuesday, November 7, 2023
Titan, Register, NYSE, KVUE, Registration statement, Court, I-Space (Chinese company), Advertising, Phenylephrine, Prospectus, Insurance, Tobacco, IPO

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Kenvue Inc.: Please contact the Portnoy Law Firm to recover your losses; December 8, 2023 deadline.

Retrieved on: 
Tuesday, November 7, 2023
FDA, IPO, Register, NYSE, KVUE, Decongestant, Registration statement, News, PE, Phenylephrine, Prospectus, Risk, Nasal congestion, Johnson & Johnson, Defendant, Security (finance), Pharmaceutical industry

​LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) investors that a lawsuit filed on behalf of investors that purchased Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2023 initial public offering (the “IPO” or “Offering”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • However, shortly after the IPO, an FDA panel unanimously declared that oral forms of PE were ineffective in relieving nasal congestion.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

KENVUE INC. (NYSE: KVUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Kenvue Inc.

Retrieved on: 
Tuesday, November 7, 2023
IPO, Register, NYSE, Food, KVUE, Registration statement, Court, Disclosure, Complaint, Phenylephrine, Prospectus, District court, Advertising, Food and Drug Administration, Security (finance)

If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.

Key Points: 
  • If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.